Literature DB >> 6324413

Bone marrow alterations induced in mice with inhalation of chrysotile asbestos.

G A Boorman, J H Dean, M I Luster, B Adkins, A Brody, H L Hong.   

Abstract

The effect of chrysotile asbestos exposure on bone marrow and immune parameters was examined in mice at 2, 12, and 26 weeks following a 3-day inhalation exposure. Ultrastructural examination revealed that the fibers were deposited primarily at alveolar duct bifurcations within the centriacinar region of the lung. Histological pulmonary changes were minimal, but by 26 weeks early asbestosis characterized by clusters of macrophages and minimal fibrosis were present in the centriacinar region of the lung. Lymphoproliferative responses, antibody levels, and number of plaque forming cells were not significantly altered in exposed mice. Pulmonary macrophages, but not peritoneal macrophages, showed evidence of activation in the chrysotile-exposed mice at 26 weeks following exposure. The most striking change was the depression of the number of bone marrow pluripotent stem cells (CFU-S) and marrow granulocyte macrophage progenitors (CFU-GM) which were lower at all three postexposure examinations. It is felt that the depression of bone marrow progenitors in asbestos-exposed mice may have relevance to the leukopenia reported in workers with occupational history of asbestos exposure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6324413     DOI: 10.1016/0041-008x(84)90259-x

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  2 in total

Review 1.  Nonpulmonary outcomes of asbestos exposure.

Authors:  Melisa Bunderson-Schelvan; Jean C Pfau; Robert Crouch; Andrij Holian
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

2.  Immunological studies on mice exposed subacutely to methyl isocyanate.

Authors:  A N Tucker; J R Bucher; D R Germolec; M T Silver; S J Vore; M I Luster
Journal:  Environ Health Perspect       Date:  1987-06       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.